Evidence map›Paper›PMID 36358719›Full record

ArticleCancers2022

CXCL8 Up-Regulated LSECtin through AKT Signal and Correlates with the Immune Microenvironment Modulation in Colon Cancer.

Shaojun Fang, Xianshuo Cheng, Tao Shen, Jian Dong, Yunfeng Li, Zhenhui Li, Linghan Tian, Yangwei Zhang, Xueyan Pan, Zhengfeng Yin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Mechanistic Insights into Tumorigenesis from Serum Proteins.medRxiv : the preprint server for health sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shaojun FangDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Xianshuo ChengDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Tao ShenDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Jian DongDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Yunfeng LiDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Zhenhui LiDepartment of Radiology, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Linghan TianDepartment of Yunnan Tumor Research Institute, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Yangwei ZhangDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Xueyan PanDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Zhengfeng YinMolecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China.
Zhibin YangDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming 650118, China.
Kunming Medical University · CNEastern Hepatobiliary Surgery Hospital · CN

Funding

Famous Doctor" Fund Project of Yunnan Province (2021)Innovation Fund for Postgraduates of Kunming Medical University (2022S314)National Natural Science Foundation of China (82060516)Yunnan Fundamental Research Projects (202101AY070001-167)、(202201AY070001-134)
6 · The paper itself

Abstract

backgroundThe role of CXCL8 and LSECtin in colon cancer liver metastasis and immune checkpoint inhibitors (ICIs) treatment effect were widely recognized. However, the regulatory role of CXCL8 on LSECtin is still unclear.

methodsThe expression of CXCL8 or LSECtin was analyzed by TCGA database, and verified by GES110225 and clinical samples. The relationship between the expression of CXCL8 or LSECtin and immune cells infiltration, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, Gene Ontology (GO) items, stromal score, Estimation of STromal and Immune cells in MAlignant Tumours (ESTIMAT) immune score, tumor mutation burden (TMB), mismatch repair gene and immune checkpoints expression were analyzed by Spearman. The effects of CXCL8 on LSECtin expression, proliferation, and invasion ability were clarified by recombinant CXCL8 or CXCL8 interfering RNA.

resultsIn colon cancer, the expression of CXCL8 was higher, but LSECtin was lower than that in normal mucosa. The expression of CXCL8 or LSECtin was significantly positively correlated with immune cells infiltration, stromal score, ESTIMATE immune score, TMB, and immune checkpoints expression. The expression of LSECtin was closely related to the cytokine-cytokine receptor interaction pathway and response of chemokine function, such as CXCL8/CXCR1/2 pathway. There was a significant positive correlation between the expression of CXCL8 and LSECtin in colon cancer. CXCL8 up-regulated LSECtin through AKT signal and promoted the proliferation and invasion ability of colon cancer.

conclusionsCXCL8 up-regulated LSECtin by activating AKT signal and correlated with the immune microenvironment modulation in colon cancer.

Indexed as

colon cancerCXCL8immune microenvironmentliver metastasisLSECtin

Identifiers

PMID36358719
PMCPMC9657600
OpenAlexW4307941964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.